
Benefits of Treating Hemophilia with Factor Concentrate
Also Available In: Japanese Treating people with hemophilia with safe, regulated plasma-derived factor concentrate directly reduces the social and economic
Year: 2007
Language: English
Author(s): World Federation of Hemophilia
Format: Document
A summary of discussions held at the World Federation of Hemophilia’s Global Forum on the Safety and Supply of Hemophilia Treatment Products, which brings together patient groups, healthcare providers, regulators, industry representatives, and not-for-profit fractionators.

Also Available In: Japanese Treating people with hemophilia with safe, regulated plasma-derived factor concentrate directly reduces the social and economic

Also Available In: Japanese This fact sheet demonstrates the benefits of providing basic treatment and care to people with hemophilia.

In this monograph, the author offers his perspective on the risk of infection from recombinant and plasma-derived products.

This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Russian A multifaceted

Small pool heat-treated intermediate purity concentrate may be the most suitable and cost-effective solution for some countries attempting sufficiency and

This monograph provides guidelines for the production of single-donor cryoprecipitate.